Abstracts from ASH 2019

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England 

Andrea Kuhnl, et al.

In this study, 122 patients were treated with axicabtagene ciloleucel and tisagenlecleucel. Details on bridging therapy, treatment-related toxicities and outcomes will be provided at the meeting, by which time 62 patients will have completed their 3 months PET response assessment

Abstract n. 767

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Samantha Jaglowski, et al.

In the real-world, tisa-cel has similar efficacy and improved safety in DLBCL patients. OOS product (viability 60-80%) does not impact efficacy

Abstract n. 766

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Samantha Jaglowski, et al.

In the real-world, tisa-cel has similar efficacy and improved safety in DLBCL patients. OOS product (viability 60-80%) does not impact efficacy

Abstract n. 766

Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience

Marie-Emilie Dourthe, et al.

Report of experience treating children with ALL at two hospitals in France in both clinical trials and the commercial setting. Results confirmed the efficacy of CTL019 with high response rates and encouraging outcomes in a heavily pretreated patient population

Abstract n. 3876

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Jakub Svoboda, et al.

Three-month complete response rates are considered reasonably predictive of outcome for CART19 therapies. Bendamustine as LDC for tisa-cel performs well outside of a clinical trial, is an option for LDC before tisa-cel therapy for pts with r/r aggressive B-cell lymphomas treated in the outpatient setting, and may have an improved safety profile with regard to cytopenias

Abstract n. 1606